J. Nielsen

发表

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

Jordan M. Graff, Michael B. Goldstein, Khoi D. Tran, 2022, The Lancet.

Clinicopathologic case report: scleral buckle associated nontuberculous mycobacterial scleritis

R. Gieser, J. Perlman, J. Nielsen, 2004, Seminars in ophthalmology.

ORAL MIFEPRISTONE FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY

L. Jampol, J. Nielsen, 2011, Retina.

Bronchogenic metastasis to the gingiva.

N. Staalsen, J. Nielsen, 1992, Oral surgery, oral medicine, and oral pathology.

INTERFERON-β-ASSOCIATED RETINOPATHY.

J. Pulido, L. Jampol, C. Blodi, 2009, Retinal cases & brief reports.

Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.

Arthur D. Fu, Ajay E. Kuriyan, Rishi P. Singh, 2022, Lancet.

Conversion of Central Subfield Thickness Measurements of Diabetic Macular Edema Across Cirrus and Spectralis Optical Coherence Tomography Instruments

Jennifer K. Sun, F. Ferris, E. Chew, 2021, Translational vision science & technology.

Retinal thickness in people with diabetes and minimal or no diabetic retinopathy: Heidelberg Spectralis optical coherence tomography.

N. Bressler, S. Bressler, S. Grover, 2012, Investigative ophthalmology & visual science.

High-Dose Aflibercept for Neovascular AMD and DME in Suboptimal Responders to Standard-Dose Aflibercept

J. Nielsen, D. D. Saggau, K. Alliman, 2023, Journal of vitreoretinal diseases.

Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration

C. Wykoff, J. Brill, L. Greene, 2018, Journal of managed care & specialty pharmacy.

Assessing the Effect of Personalized Diabetes Risk Assessments During Ophthalmologic Visits on Glycemic Control: A Randomized Clinical Trial.

Lloyd Paul Aiello, Jared Nielsen, Neil M Bressler, 2015, JAMA ophthalmology.

Rifampin induced hepatotoxicity during treatment for chronic central serous chorioretinopathy.

J. Nelson, J. Nielsen, D. D. Saggau, 2014, Retinal cases & brief reports.

Implantation Site of a Port Delivery System With Ranibizumab: Anterior Segment Optical Coherence Tomography Evaluation

B. Berger, Shamika Gune, J. Nielsen, 2022, Journal of vitreoretinal diseases.

Patient-, Caregiver-, and Eye Care Professional-reported Burden of Geographic Atrophy Secondary to Age-related Macular Degeneration

Rishi P. Singh, J. Schmier, Sunil S. Patel, 2019, American Journal of Ophthalmic Clinical Trials.

DEFINING “STRONG” VERSUS “WEAK” RESPONSE TO ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR CENTER-INVOLVED DIABETIC MACULAR EDEMA

Jennifer K. Sun, F. Ferris, S. Solomon, 2022, Retina.

Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial

R. Shah, P. Campochiaro, S. Gupta, 2023, Japanese Journal of Ophthalmology.

MULTIMODAL IMAGING OF WHITE AND DARK WITHOUT PRESSURE FUNDUS LESIONS

Helen K. Li, A. Fawzi, L. Jampol, 2014, Retina.

INTRAVITREAL ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO OCULAR HISTOPLASMOSIS SYNDROME

Tyler A. Fick, J. Nielsen, C. H. Barnes, 2012, Retina.

Mifepristone treatment of chronic central serous chorioretinopathy.

L. Yannuzzi, R. Weinreb, L. Jampol, 2007, Retina.